🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Sporadic Degenerative Ataxia With Adult Onset: Natural History Study

Recruitingn/aAges 40 Years - anyAllAtaxia Study Group
NCT02701036 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The key goals of SPORTAX-NHS is to compare the phenotype of multiple system atrophy of cerebellar type (MSA-C) and sporadic adult onset ataxia of unknown aetiology (SAOA) and to determine the rate of disease progression in both groups including determination of the factors that predict the development of MSA-C vs. SAOA, and at which time after onset of ataxia, a reliable distinction between both disorders is possible. The planned study will also allow to collect blood samples and other biomaterials from patients with sporadic ataxia, which will be useful for future genetic and biomarker studies.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Progressive ataxia * Disease onset after the age of 40 years * Informative and negative family history (no similar disorders in first- and second-degree relatives; parents older than 50 years, or, if not alive, age at death of more than 50 years, no consanguinity of parents) Exclusion Criteria: * No established acquired cause of ataxia Clinical exclusion criteria: * No onset of ataxia in association with stroke, encephalitis, sepsis, hyperthermia or heat stroke; * no chronic diarrhea; * no unexplained visual loss; * no alcohol abuse; * no chronic intake of anticonvulsant drugs; * no other toxic causes; no malignancies; * no rapid progression (development of severe ataxia in less than 12 weeks); * no insulin-dependent diabetes mellitus Imaging exclusion criteria: * No evidence of multiple sclerosis, ischemia, hemorrhage or tumor of the posterior fossa; * absence of signal abnormalities on T2/FLAIR-images except abnormalities compatible with MSA Laboratory exclusion criteria: * Negative molecular genetic testing for FRDA (only required if there is no cerebellar atrophy on MRI, SCA1, SCA2, SCA3, SCA6, FMR1 premutation (only required if prominent tremor, cognitive impairment and signal abnormality on T2/FLAIR images in the middle cerebellar peduncle); * antineuronal antibodies negative (only required, if disease duration less than 3 years); * normal levels of vitamin B12; * VDRL negative; * normal thyreoid function
💊

What it tests

  • Not listed
📍

Where

14 sites
Department of Neurology, Medical University, Innsbruck
Innsbruck, Austria
Universitätsmedizin Berlin Charité
Berlin, Germany
Department of Neurology, University of Bonn
Bonn, Germany
Department of Neurology, University Clinic Essen, University of Duisburg-Essen
Essen, Germany
Department of Neurology, University of Frankfurt
Frankfurt, Germany
Hamburg UKE Abt. Neuropädiatrie
Hamburg, Germany
Otto-von-Guericke Universität Magdeburg
Magdeburg, Germany
Friedrich-Baur-Institut an der Neurologischen Klinik
München, Germany

…and 6 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy